AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16931218
Drug: Once every
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once every 2 weeks subcutaneous epoetin beta (group 2w)
Trial: 16931218
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous epoetin beta (group 1w)
Trial: 12297476
Drug: Nimodipine on
RxNorm normalized name: Nimodipine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine on the basis of conventional therapy lasting till 30 days after injuries
Trial: 12297476
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy including craniotomy, hemostasis, dehydration, anti-infection and corticosteroid administration
Trial: 6602783
Drug: Bepridil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (2 mg/kg, intravenous infusion)
Trial: 29107495
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA
Trial: 17664499
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT)‐type intervention plus a consultation letter
Trial: 17664499
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT)‐type intervention
Trial: 12105840
Drug: rFVIIa (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (4 doses: 5, 20, 80, and 120 microg/kg)
Trial: 31978429
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled corticosteroids (ICS)
Trial: 22985270
Drug: Long-acting β2-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting β2-agonists and anticholinergics
Trial: 2678856
Drug: Non-steroid treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid treatment
Trial: 2339965
Drug: Pyridostigmine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (30 mg every 8 h)
Trial: 25010374
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (2.5 mg daily)
Trial: 21050319
Drug: Rifaximin 1,100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 1,100 mg once daily for 2 weeks
Trial: 21050319
Drug: Rifaximin 1,100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 1,100 mg once daily
Trial: 2517009
Drug: Rilmenidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine (1 mg)
Trial: 28859020
Drug: 2-stage nonoperative
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-stage nonoperative treatment with additional diagnostic block if regular 2 weeks medication was not effective
Trial: 26553690
Drug: PsA‐TT vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsA‐TT vaccine
Trial: 26553682
Drug: PsACWY vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsACWY vaccine
Trial: 12544730
Drug: Idraparinux (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idraparinux (2.5, 5, 7.5 or 10 mg)
Trial: 27433335
Drug: 6-week self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week self-management training program (manual therapy, education, home exercises) with instructional workbook and video and a pedometer
Trial: 19334068
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m², four weekly infusions)
Trial: 9510100
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) treatment
Trial: 12957701
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation using Integrated Psychological Treatment (IPT)
Trial: 8243685
Drug: Kallidinogenase (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kallidinogenase (600 units by mouth daily for 12 weeks)
Trial: 3519529
Drug: Propranolol (60-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60-320 mg/day)
Trial: 30272850
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplements
Trial: 29428785
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplements only
Trial: 29322301
Drug: DHEA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (100 mg daily for 4 weeks)
Trial: 18832434
Drug: Flupentixol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 0.5 mg
Trial: 12397530
Drug: Felted foam
RxNorm normalized name: BELT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felted foam therapy
Trial: 29052766
Drug: l-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine supplementation (6.4 g orally/day)
Trial: 15363419
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injections (ESI)
Trial: 8672931
Drug: Continuous i.v.‐tocolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v.‐tocolysis and oral application of magnesium sulfate
Trial: 1792400
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg/kg
Trial: 23158128
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus fentanyl 1 µg/ml
Trial: 23158128
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus fentanyl 2 µg/ml
Trial: 23158128
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus fentanyl 3 µg/ml
Trial: 17196293
Drug: peginterferon/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon/ribavirin therapy
Trial: 12472620
Drug: Maca Gelatinizada
RxNorm normalized name: MACA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca Gelatinizada 1,500 mg
Trial: 9696953
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg daily for 6 days)
Trial: 2684076
Drug: Intramuscular LEFAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular LEFAC (bovine liver extract containing folic acid and cyanocobalamin)
Trial: 31135817
Drug: Galcanezumab, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab, 120 mg
Trial: 29098381
Drug: Lapatinib 1500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1500-mg administered orally once daily on study days 4 through 11
Trial: 21282539
Drug: Carboplatin (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (one infusion at 7 × (glomerular filtration rate + 25) based on EDTA)
Trial: 21282539
Drug: Carboplatin (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (at least 99% of the 7 × AUC dose)
Trial: 21282539
Drug: Carboplatin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (lower doses)
Trial: 20137694
Drug: 52-week rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52-week rabeprazole treatment
Trial: 11259888
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg potassium diclofenac orally 1 hour preoperatively and placebo 30 minutes postoperatively (Preop group)
Trial: 11259888
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg potassium diclofenac 1 hour preoperatively and 25 mg diclofenac 30 minutes postoperatively (Pre+postop group)
Trial: 11444676
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) 50 mg
Trial: 20151824
Drug: rhTSH Group
RxNorm normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhTSH Group (recombinant human thyroid-stimulating hormone administration)
Trial: 15795446
Drug: Placebo (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25 mg ascorbic acid and 10 microg folate)
Trial: 15795446
Drug: Anemic mothers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemic mothers (both treatment and placebo)
Trial: 23640612
Drug: Brinzolamide 1%/brimonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC)
Trial: 23640612
Drug: Brimonidine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine monotherapy
Trial: 21561700
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg per day for patients below 50 kg and 100 mg per day for patients over 50 kg)
Trial: 12192663
Drug: HIV patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV patients on anti-viral medication
Trial: 2192197
Drug: Continuous 72
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 72 hour infusion (CI) of Adriamycin, 60 mg/m2 every 3 weeks
Trial: 31129369
Drug: Non-responders re-randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders re-randomized to step-up treatment
Trial: 11573660
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA)
Trial: 23490041
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg clopidogrel load
Trial: 23490041
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg clopidogrel load
Trial: 23490041
Drug: Atorvastatin reload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin reload (80 mg + 40 mg)
Trial: 17613274
Drug: Combination tablets
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablets (600mg calcium + 300mg magnesium + 100IU vitamin D3)
Trial: 17613274
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate tablets (1000mg calcium)
Trial: 11479391
Drug: Methylphenidate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.2 mg/kg) + L-Dopa (2 mg/kg per h)
Trial: 7922005
Drug: Control reagent
RxNorm normalized name: urinalysis control reagent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control reagent combination using IgG1 control antibody labeled with PE.
Trial: 5071698
Drug: Frequent review
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent review by the doctor after the first prescription and cautionary advice to the patient
Trial: 26607942
Drug: Resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (500 mg twice daily)
Trial: 12136475
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide
Trial: 1422715
Drug: Bioptycut 14-G
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bioptycut 14-G (B14)
Trial: 1422715
Drug: Tru-Cut 14-G
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tru-Cut 14-G (T14)
Trial: 1422715
Drug: Bioptycut 18-G
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bioptycut 18-G (B18)
Trial: 6094194
Drug: Bromocriptin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptin (2.5 mg, twice daily for 4 days)
Trial: 30213173
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no parecoxib administration)
Trial: 27250001
Drug: CEFci arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CEFci arm (5‐Fu 200 mg/m(2) daily by 24‐h continuous infusion and epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) intravenous bolus on day 1)
Trial: 27250001
Drug: CEF arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CEF arm (cyclophosphamide 600 mg/m(2), epirubicin 100 mg/m(2), and 5‐Fu 600 mg/m(2) i.v. on day 1)
Trial: 27250001
Drug: EC arm
RxNorm normalized name: Drive Cast Protec Arm 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC arm (epirubicin 100 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1)
Trial: 11441423
Drug: Ecopipam 10
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 10 mg p.o.
Trial: 11441423
Drug: Ecopipam 25
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 25 mg p.o.
Trial: 11441423
Drug: Ecopipam 100
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 100 mg p.o.
Trial: 11441423
Drug: Cocaine 25
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 25 mg/70 kg i.v.
Trial: 11441423
Drug: Cocaine 50
RxNorm normalized name: cocaine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 50 mg/70 kg i.v.
Trial: 7523724
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy combined with androgen deprivation
Trial: 7523724
Drug: Conformal 3-dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal 3-dimensional radiation therapy
Trial: 3372718
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg daily for 6 weeks)
Trial: 31145366
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus fire needle therapy
Trial: 25016389
Drug: Procedural sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedural sedation and analgesia (intravenous midazolam plus fentanyl)
Trial: 16816394
Drug: Morphine in
RxNorm normalized name: morphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine in ropivacaine (Group M, n=30)
Trial: 8228792
Drug: Immunoadsorption (IMA)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IMA) with combined anticoagulation using heparin and citrate
Trial: 8228792
Drug: Dextran sulfate
RxNorm normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran sulfate adsorption (DSA) with heparin exclusively
Trial: 28499657
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care (dose-matched, goal-oriented)
Trial: 17874889
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (STX)
Trial: 16449099
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg/d for the first week, 20 mg/d for the second week)
Trial: 16449099
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg/d for the first week, 50 mg/d for the second week)
Trial: 9341573
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment arm
Trial: 9341573
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment arm
Trial: 15983962
Drug: Spironolactone, 50
RxNorm normalized name: Spironolactone, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone, 50 mg, orally twice daily for 2 weeks
Trial: 8732962
Drug: Dexamethasone 0.05
RxNorm normalized name: dexamethasone 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.05 mg
Trial: 8732962
Drug: Dexamethasone 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.125 mg
Trial: 8732962
Drug: Dexamethasone 0.25
RxNorm normalized name: dexamethasone 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.25 mg
Trial: 1815967
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg emiglitate
Trial: 6808657
Drug: Phenoxymethylpenicillin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 0.4 g
Trial: 6808657
Drug: Phenoxymethylpenicillin 1
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 1 g
Trial: 6808657
Drug: Phenoxymethylpenicillin 2
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 2 g
Trial: 27814710
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 80 ppm as an adjunctive therapy for severe malaria
Trial: 10077718
Drug: Hypnosis/self-hypnosis (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis/self-hypnosis (5 sessions, half an hour each, weekly intervals)
Trial: 10077718
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (2 sessions, half an hour each, weekly intervals)
Trial: 10077718
Drug: Talks to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talks to the doctor (2 sessions, half an hour each, weekly intervals)
Trial: 31661693
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT) for 20 min before 10 min language therapy daily for 4 weeks
Trial: 25142820
Drug: Fast dissolving
RxNorm normalized name: Mucinex Sinus-Max Day/Night Fast Dissolving Gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast dissolving oral film formulation of flupentixol dihydrochloride (2% HPMC)
Trial: 25142820
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available oral tablets of flupentixol dihydrochloride
Trial: 16188958
Drug: Family based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family based behavioural treatment for obese children for two years
Trial: 9042993
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg three times daily)
Trial: 1497688
Drug: beta-acetyldigoxin oral
RxNorm normalized name: acetyldigoxins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-acetyldigoxin oral solution
Trial: 1497688
Drug: beta-acetyldigoxin tablets
RxNorm normalized name: acetyldigoxins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-acetyldigoxin tablets
Trial: 31147361
Drug: Acellular porcine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular porcine collagen implant
Trial: 28604556
Drug: NeuGcGM3-based vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuGcGM3-based vaccine (200 μg) administered every 2 weeks for 5 doses, followed by monthly reimmunizations to complete 15 doses, combined with Montanide ISA51 as adjuvant treatment.
Trial: 28604556
Drug: NeuGcGM3-based vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuGcGM3-based vaccine
Trial: 23784727
Drug: Non-specific cognitive
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific cognitive treatment combined with cholinesterase inhibitors (ChEIs)
Trial: 21737214
Drug: Intranasal methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg)
Trial: 21737214
Drug: Alprazolam XR
RxNorm normalized name: ALPRAZOLAM 2 mg ORAL TABLET, EXTENDED RELEASE [Alprazolam XR]
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam XR (0 and 1 mg/day)
Trial: 15223851
Drug: Vardenafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (10 mg)
Trial: 14517691
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose of IFN-alpha (2.5 MU/m² per day)
Trial: 14517691
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of IFN-alpha (5 MU/m² per day)
Trial: 7518728
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment for 4 months
Trial: 2178522
Drug: Sequential terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential terbutaline (0.25 mg subcutaneously followed by another 0.25 mg subcutaneously)
Trial: 2178522
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (normal saline)